Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
| ▸ | PPARD | Q03181 | 3/20 | 0.45 |
| ▸ | PPARA | Q07869 | 2/20 | 0.45 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.45 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.45 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | DRD4 | P21917 | 3/20 | 0.44 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.41 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.41 |
| ▸ | HTR7 | P34969 | 1/20 | 0.41 |
| ▸ | HTR1A | P08908 | 1/20 | 0.41 |
| ▸ | SMO | Q99835 | 1/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4333350 | 0.89 | SMO (0.52) | ALDH1A1KDM4EDRD4HTTCHRNA7 | |
| SCHEMBL4327075 | 0.86 | ALDH1A1 (0.47) | ALDH1A1KCNH2ADRA1DADRA1AADRA1B | |
| SCHEMBL4322688 | 0.85 | ADRA1D (0.44) | ALDH1A1ADRA1DADRA1AADRA1BKDM4E | |
| SCHEMBL4328990 | 0.84 | HTR1A (0.47) | ALDH1A1KDM4EDRD4HTTCHRNA7 | |
| SCHEMBL4331547 | 0.84 | POLB (0.50) | ALDH1A1KDM4EDRD4HTTCHRNA7 | |
| SCHEMBL4338271 | 0.82 | HTR1A (0.44) | ALDH1A1KDM4EDRD4HTR1A | |
| SCHEMBL4338375 | 0.82 | ALDH1A1 (0.44) | ALDH1A1KDM4EDRD4HTTCHRNA7 | |
| SCHEMBL4319530 | 0.80 | SMN1; SMN2 (0.52) | ALDH1A1ADRA1DADRA1AADRA1BKDM4E | |
| SCHEMBL4324444 | 0.80 | DRD2 (0.57) | ALDH1A1KDM4EDRD4 | |
| SCHEMBL4335040 | 0.79 | HTR1A (0.44) | ALDH1A1KDM4EDRD4HTR7HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090069340-A1 | Pyrazolone Compounds As Metabotropic Glutamate Receptor Agonists For The Treatment Of Neurological And Psychiatric Disorders | ASTRAZENECA AB (SE) | 2009-03-12 | — | — | US | disclosed |
| US-20090069340-A1 | Pyrazolone Compounds As Metabotropic Glutamate Receptor Agonists For The Treatment Of Neurological And Psychiatric Disorders | ASTRAZENECA AB (SE) | 2009-03-12 | — | — | US | disclosed |
| US-20090069340-A1 | Pyrazolone Compounds As Metabotropic Glutamate Receptor Agonists For The Treatment Of Neurological And Psychiatric Disorders | ASTRAZENECA AB (SE) | 2009-03-12 | — | — | US | disclosed |
| WO-2006071730-A1 | PYRAZOLONE COMPOUNDS AS METABOTROPIC GLUTAMATE RECEPTOR AGONISTS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS | ASTRAZENECA AB (SE) | 2006-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069340-A1 | Pyrazolone Compounds As Metabotropic Glutamate Receptor Agonists For The Treatment Of Neurological And Psychiatric Disorders | GRIN1, GRM1, GRIN3A | ALDH1A1 1785/4885KCNH2 610/4885PPARD 363/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.